George M. Matuschak MD
Critical Care Medicine, Interstitial Lung Diseases, Pulmonary Vascular Medicine, Sleep Medicine
Program Director, PHA accredited Regional Clinical Program in Pulmonary Hypertension, Mercy Clinic St. Louis; Division Director emeritus, Pulmonary, Critical Care & Sleep Medicine; Professor of Medicine, Saint Louis University School of Medicine
Join to View Full Profile
621 S New Ballas RdSte 228ACreve Coeur, MO 63141
Phone+1 314-251-4966
Fax+1 314-251-4588
Dr. Matuschak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. George Matuschak is a pulmonologist in Creve Coeur, MO and is affiliated with Mercy Hospital St. Louis. He received his medical degree from Lewis Katz School of Medicine at Temple University and has been in practice 40 years. He specializes in pulmonology, critical care medicine, pulmonary vascular medicine, and sleep medicine.
Education & Training
UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1981 - 1983
UPMC Medical EducationResidency, Anesthesiology, 1980 - 1981
University of Rochester Medical CenterResidency, Internal Medicine, 1977 - 1980
Lewis Katz School of Medicine at Temple UniversityClass of 1977
Certifications & Licensure
MO State Medical License 1987 - 2026
PA State Medical License 1980 - 2006
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Fellow, American College of Chest Physicians
- America's Top Doctors Castle Connolly, 2011-2023
- Best Doctors of America 2008-2023
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 10 citationsAdenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis.Constance N. Wilson, Constance O. Vance, Melissa G. Lechner, George M. Matuschak, Andrew J. Lechner
European Journal of Pharmacology. 2014-10-05 - 48 citationsA phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.Alejandro C. Arroliga, Robert A. Balk, Chad M. Cannon, Nathan C. Dean, Phillip Dellinger
Critical Care Medicine. 2013-03-01 - 5 citationsA novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis.Constance N. Wilson, Constance O. Vance, Timothy M. Doyle, David S. Brink, George M. Matuschak
Innate Immunity. 2012-06-01
Grant Support
- Liver/Lung Interactions During Gram Negative EndotoxemiaNational Institute Of General Medical Sciences1999–2003
- Liver Lung Interactions During Gram Negative EndotoxemiaNational Institute Of General Medical Sciences1999
- Liver-Lung Interactions During Gram-Negative EndotoxemiaNational Institute Of General Medical Sciences1990–1998
Professional Memberships
- Member
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
